Generic Biotech drugs may be coming
Jun 23, 2007
The WSJ reports that a bipartisan group of several key senators, including Democrats Edward Kennedy (MA) and Hillary Clinton (NY) and Republicans Orrin Hatch (UT) and Michael Enzi (WY) have reached a deal to create a legal pathway that clears the road for generic biotech drugs, which they coin “biosimilars”.
This has been a long time coming, but is a needed reform to create a “generic” for the biotech industry– where patents are beginning to expire but replacements are not legally available.
Furthermore, broad experience in the formulation of these drugs can only help train entrants as they move up the value chain into full biotech pharmaceutical innovators.
